Research programme: TRPV1 receptor antagonists - Grunenthal/Medifron

Drug Profile

Research programme: TRPV1 receptor antagonists - Grunenthal/Medifron

Alternative Names: MDR-16523

Latest Information Update: 31 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medifron DBT
  • Developer Grunenthal; Medifron DBT
  • Class
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic neuropathies; Postherpetic neuralgia

Most Recent Events

  • 31 Jul 2016 Preclinical trials in Diabetic neuropathies in South Korea (unspecified route)
  • 31 Jul 2016 Preclinical trials in Postherpetic neuralgia in South Korea (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top